LP01™ + LLC02+ LDD01 (FLOR-EN ADULTS)
Gastroenterology
IBD / Abdominal surgery
Ameliorates dysbiosis and reduces symptoms like abdominal pain and bloating for people with IBD, as well as for those who have had abdominal surgery or a colonoscopy.
1, 2, 3) LP01 1 billion cells + LLC02 800 million cells + LLD01 200 million cells
Blend
Finished dosage form
1) Bonavina L, et al. Abincol® (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01), an oral nutraceutical, pragmatic use in patients with chronic intestinal disorders. Acta Biomed. 2019 Jul 10;90(7-S):8-12. DOI: 10.23750/abm.v90i7-S.8649
2) Bonavina L, et al. Post-surgical intestinal dysbiosis: use of an innovative mixture (Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, Lactobacillus delbrueckii LDD01). Acta Biomed. 2019 Jul 10;90(7-S):18-23. DOI: 10.23750/abm.v90i7-S.8651
3) Bonavina L, et al. Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation. Acta Biomed. 2019 Jul 10;90(7-S):13-17. DOI: 10.23750/abm.v90i7-S.8650
a) Deidda F, et al. How Probiotics may Kill Harmful Bacteria: The in vitro Activity against Some Haemolytic Strains. J Prob Health, 2020. Vol. 8 Iss.2 No: 216. DOI: 10.35248/2329-8901.20.8.216
b) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
c) Amoruso A. et al. A Systematic Evaluation of the Immunomodulatory and Functional Properties of Probiotic Bifidobacterium Breve BR03 (DSM 16604) Lactobacillus plantarum LP01 (LMG P-21021). J Prob Health. 2019; 7:214. Doi: 10.35248/2329-8901.19.7.214
Allergy & Immunology
Immune stimulation / Respiratory tract infections
Reduces the severity of symptoms, the occurrence of clinical relapses, and the need for extra medication in patients with laryngotracheitis, acute and chronic rhinosinusitis, otitis media, or pharyngotonsillitis.
1) BS01 10 billion CFU + LR04 10 billion CFU + LP02 10 billion CFU + FOS
Single strain
Blend
Finished dosage form
1) Gelardi M, et al. A probiotic mixture in patients with upper respiratory diseases: the point of view of the otorhinolaringologist. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 1):5-10
2) La Mantia I, et al. Probiotics in the add-on treatment of laryngotracheitis: a clinical experience. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 1):35-40
3) La Mantia I, et al. Probiotics in the add-on treatment of pharyngotonsillitis: a clinical experience. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 1):11-18
4) Gelardi M, et al. Probiotics in the add-on treatment of otitis media in clinical practice. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 1):19-26
5) La Mantia I, et al. Probiotics in the add-on treatment of rhinosinusitis: a clinical experience. J Biol Regul Homeost Agents. 2020 Nov-Dec;34(6 Suppl. 1):27-34
